[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nail-psoriasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nail-psoriasis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,75,96,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100634926","clinical-study-on-the-medical-device-proxera-psomed-30-for-the-treatment-of-nail-psoriasis-evaluation-of-safety-and-efficacy-100634926",false,"NCT07546032","Clinical Study on the Medical Device PROXERA PSOMED 30 for the Treatment of Nail Psoriasis: Evaluation of Safety and Efficacy","Evaluation of the Safety and Efficacy of the Medical Device PROXERA PSOMED 30 in the Treatment of Nail Psoriasis: a Sponsored, Interventional, Single-center, Randomized, Single-site, Intrapatient Controlled Study (NAPSI)","NAPSI","Inclusion Criteria:\n\n* Diagnosis of Psoriasis\n* Diagnosis of nail psoriasis for at least 6 months (NAPSI ≥ 3)\n* Male or female\n* Age between 18 and 65 years\n* Willingness to participate in the study and signing the informed consent form\n\nExclusion Criteria:\n\n* Known hypersensitivity or intolerance to any component of the product.\n* Concomitant therapy with systemic immunomodulatory drugs (e.g., cyclosporine, apremilast), except methotrexate (MTX), the use of which will be compatible with the study.\n* Concomitant therapy with biologic agents such as anti-TNFα, anti-IL17, or anti-IL23.\n* Concomitant topical therapy with topical steroids (TCS), topical calcineurin inhibitors (TCI), vitamin D analogues, and combinations.\n* Pregnant or breastfeeding women","ALL","18 Years","65 Years",{"count":21,"type":22},21,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this interventional clinical study is to evaluate the safety and efficacy of PROXERA PSOMED 30, a topical medical device containing 30% urea, for the treatment of nail psoriasis in adults with nail psoriasis. The primary question the study aims to answer is whether PROXERA PSOMED 30 improves the clinical signs of nail psoriasis more effectively than a control treatment (Vaseline).\n\nResearchers will compare two similar target nails in the same participant, one treated with PROXERA PSOMED 30 and the other with Vaseline, to determine whether the active treatment leads to greater improvement in Nail Psoriasis Severity Index (NAPSI) scores over 24 weeks. The study will also evaluate local tolerability, patient satisfaction, and digital photographs of the treated nails.\n\nParticipants will be men or women between the ages of 18 and 65 with nail psoriasis for at least 6 months and a target NAPSI nail score of 3 or higher. A total of 21 participants is expected.\n\nParticipants will:\n\napply PROXERA PSOMED 30 to one target nail and petroleum jelly to the opposite target nail twice daily for 24 weeks; attend follow-up visits at baseline and after 4, 12, and 24 weeks; undergo nail assessments using the NAPSI score; have digital photographs of treated nails; report tolerability, satisfaction, and any adverse events during the study.",[28],"Nail Psoriasis",[28,30,31,32,33,34,35,36,37],"Psoriasis","PROXERA PSOMED 30","Urea","Topical Medical Device","Intra-patient Controlled Study","Single-Blind Study","Nail Psoriasis Severity Index","Petrolatum","RECRUITING","2026-07-26",{"date":41,"type":42},"2026-07-28","ACTUAL",{"date":44,"type":42},"2026-05-12",{"date":46,"type":22},"2027-02-08",{"name":48,"class":49},"ICIM International S.r.l.","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":50},"100648825","phase-4-an-open-label-trial-to-evaluate-efficacy-and-safety-of-roflumilast-03-cream-for-chronic-plaque-and-nail-psoriasis-100648825","NCT07725822","An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis","Inclusion Criteria:\n\n1. Participants legally competent to sign and give informed consent.\n2. Males and females ages 12 years of age and older.\n3. Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator. Stable psoriasis for the past 6 months and stable nail disease for the past 6 months.\n4. Psoriasis vulgaris on the face, extremities, trunk, and\u002For intertriginous areas and groin (excluding the scalp, palms and soles).\n5. Nail psoriasis affecting ≥3 fingernails on hands.\n6. An Investigator's Global Assessment of disease severity (IGA) or (I-IGA) of at least Almost Clear ('1') at Baseline\n7. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2) (if not combined).\n\n   * In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.\n   * Highly effective forms of contraception include: oral\u002Fimplant\u002Finjectable\u002Ftransdermal contraceptives, intrauterine device, and partner's vasectomy.\n   * If barrier methods are used (e.g., condom with spermicide, diaphragm with spermicide), then 2 forms of conception are required.\n   * The use of abstinence as a contraceptive measure is acceptable as long as this is a consistent part of a lifestyle choice and an acceptable backup method has been identified if the subject becomes sexually active.\n8. In good health as judged by the Investigator, based on medical history, physical examination.\n\nExclusion Criteria:\n\n1. Subjects who cannot discontinue medication and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments (Table 1).\n2. Subjects who currently have or plan to have gel or acrylic overlays on nails during the study.\n3. Subjects who cannot discontinue nail care habits that will confound efficacy and safety assessments (e.g. buffing, filing, excessive trimming). Routine simple clipping is allowed.\n4. Subjects who cannot discontinue any nail topcoat products (e.g. hardeners, strengtheners, nail polish) Simple nail polish will be allowed for special events and removed the next day. Subject will note in diary days this occurs and the total days may not exceed 5 study days.\n5. Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.\n6. Subjects currently taking lithium or antimalarial drugs.\n7. Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris (e.g. beta blockers, ACE inhibitors).\n8. Current diagnosis of drug-induced psoriasis.\n9. Any recent infection, presence of onychomycosis or any other confounding nail disorder as determined by investigator.\n10. Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.\n11. Known allergies to excipients in roflumilast cream (petrolatum, isopropyl palmitate, methylparaben, propylparaben, diethylene glycol monoethyl ether, hexylene glycol, cetylstearyl alcohol, dicetyl phosphate and ceteth-10 phosphate).\n12. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.\n13. Previous treatment with any topical PDE4i. Subjects who have received oral roflumilast (Daliresp®, Daxas®) or other PDE4 inhibitors (apremilast) within the past 6 months.\n14. Known or suspected:\n\n    * severe renal insufficiency or moderate to severe liver impairment (Child-Pugh B or C)\n    * known HIV infection\n    * hypersensitivity to component(s) of the study drugs\n    * history of severe depression, suicidal ideation\n15. Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication.\n16. Subjects with a history of a major surgery within 4 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study.\n17. Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.\n18. Subjects who are family members of the clinical study site, clinical study staff \u002F sponsor, or family members of enrolled subjects.\n19. Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.\n20. History of and\u002For concurrent condition of serious hypersensitivity (anaphylactic shock or anaphylactoid reaction) to PDE-4 inhibitors.\n21. Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.",{"count":58,"type":22},15,[60],"PHASE4","This is an open label trial in subjects ≥12 years of age and older with chronic plaque psoriasis and moderate to severe nail psoriasis.\n\nEligible participants will apply roflumilast 0.3% cream daily for 24 weeks to affected nails daily for the entire study duration and to psoriasis plaques daily until clear.",[63,28],"Chronic Plaque Psoriasis",[63,28],"NOT_YET_RECRUITING","2026-07-24",{"date":41,"type":42},{"date":69,"type":22},"2026-08",{"date":71,"type":22},"2027-08",{"name":73,"class":74},"Modern Research Associates, PLLC","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100617011","phase-2-topical-use-of-2-tofacitinib-for-nail-psoriasis-an-exploratory-clinical-study-100617011","NCT07313072","Topical Use of 2% Tofacitinib for Nail Psoriasis: an Exploratory Clinical Study","Inclusion Criteria: Age ≥ 18 years;\n\n* Presence of nail psoriasis in at least one fingernail or toenail;\n* Patients not using systemic medication, or without adequate response to systemic medication after at least 6 months of use;\n* Ability to read, understand, and sign the Informed Consent Form (ICF) and the Consent Form for Images, Presentations, and Scientific Publications.\n\nExclusion Criteria: Pregnant or breastfeeding women or those planning to become pregnant during the study period;\n\n* History of sensitivity to any components of the study product;\n* Initiation of systemic medication for nail psoriasis less than six months prior.",{"count":82,"type":22},10,[84],"PHASE2","To evaluate the efficacy and safety of topical 2% tofacitinib nail lacquer in nail psoriasis, using the NAPSI and DLQI scales before and after 26 weeks of treatment.",[28],"2026-03-16",{"date":89,"type":42},"2026-03-18",{"date":91,"type":22},"2026-03",{"date":93,"type":22},"2027-03",{"name":95,"class":74},"Hexsel Dermatology Clinic",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":50},"100595212","phase-3-study-to-assess-efficacy-safety-and-tolerability-of-a-nail-patch-in-patients-with-nail-fragility-mychosis-psoriasis-100595212","NCT07029516","Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis","A Randomized, Double Blind, Placebo-controlled, Unicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of a Multi-funtion Toe Nail Patch in Patients Affected by Nail Fragility, Nail Mychosis and Psoriasis","Inclusion Criteria:\n\n* aged 18 years or older Fragility Nails Distal Subungual Onychomycosis Nail Psoriasis affecting ≤75% of the nail bed according to a photographic documentation and to a subjective evaluation by the Investigator.\n\nExclusion Criteria:\n\n* Patients that have proximal subungual onychomycosis, if their distal subungual onychomycosis is extended into the proximal portion of the nail or if it affects \\>75% of the nail.\n* Patients with conditions known to cause abnormal nail appearance, immunosuppression and signs of severe peripheral circulatory insufficiency\n* Patients who had used topical antifungal, anti-psoriasis nail treatment within one month or systemic antifungal treatment within three months.\n* Patients who have participated in another clinical nail study during the previous three months\n* Patients who have a known allergy to any of the study treatments.\n* Patients with unrelated nail disorders: onychomycosis, nail psoriasis, genetically induced onychodystrophy.\n* Patients with other nail disorders, active or severe psoriasis elsewhere, other autoimmune or inflammatory diseases.",{"count":104,"type":22},72,[106],"PHASE3","A randomized, double blind, placebo-controlled, unicenter, parallel group study to assess the efficacy, safety and tolerability of a multi-funtion toe nail patch in patients affected by nail fragility, nail mychosis and psoriasis 72 patients in 6 subgroups Treatment duration 3 months + 1 month follow-up",[28,109,110],"Nail Damage","Mycosis",[112,113,114,115],"ONICOMYCOSIS","PATCH","UREA","PSORIASIS","2026-01-22",{"date":118,"type":42},"2026-01-26",{"date":120,"type":22},"2026-02",{"date":122,"type":22},"2026-12",{"name":124,"class":49},"Wooshin Labottach Co., Ltd.",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":142,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":50},"100577788","real-world-study-of-xeligekimab-for-moderate-to-severe-plaque-psoriasisxp-real-100577788","NCT06802848","Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)","Effectiveness and Safety of Xeligekimab in Adult Patients With Moderate to Severe Plaque Psoriasis: A Multicenter, Prospective, Real-World Study","Inclusion Criteria:\n\nPatients who meet all the following criteria will be included in this study:\n\n1. Patients 18 years of age or older;\n2. Patients with a confirmed clinical diagnosis of moderate to severe plaque psoriasis at the time of screening;\n3. Patients who are deemed suitable for xeligekimab therapy by a clinician and are anticipated to receive xeligekimab treatment for the first time;\n4. Patients who are willing to sign the informed consent form.\n\nExclusion Criteria:\n\nPatients who meet any of the following exclusion criteria will be excluded from this study:\n\n1. Patients with drug-induced psoriasis (such as new-onset or exacerbated psoriasis caused by β-blockers, calcium channel blockers, or lithium);\n2. Patients with hypersensitivity to the active ingredient or any excipient in xeligekimab injection solution;\n3. Patients with other contraindications specified in the prescribing information;\n4. Patients concurrently participating in other clinical studies;\n5. Patients under other conditions or circumstances that investigators do not consider appropriate to include.",{"count":133,"type":22},1000,"OBSERVATIONAL","Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.",[137,138,139,28,140,141],"Plaque Psoriasis","Psoriatic Arthritis","Scalp Psoriasis","Palmoplantar Psoriasis","Genital Psoriasis",[137,138,139,28,140,141,143,144,145,146,147],"Comorbidities of Psoriasis","Xeligekimab","IL-17A","GR1501","Antibodies, Monoclonal","2025-01-26",{"date":150,"type":42},"2025-01-31",{"date":152,"type":22},"2025-01-30",{"date":154,"type":22},"2026-12-31",{"name":156,"class":49},"Chongqing Genrix Biopharmaceutical Co., Ltd"]